Cholesterol changes in smoking cessation using the transdermal nicotine system. Transdermal Nicotine Study Group

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Cigarette smoking is a primary risk factor for coronary heart disease.
• Smoking cessation improves atherogenic factors, including increasing high-density lipoprotein cholesterol (HDL).
• Transdermal nicotine systems are widely used for smoking cessation.

Purpose of the Study:

• To investigate the effects of transdermal nicotine system (TTS) on cardiovascular parameters in patients abstinent from cigarette smoking.
• To examine potential dose-dependent effects of TTS on cardiovascular outcomes.

Main Methods:

• Eight cardiovascular outcome measures were assessed at baseline and Week 6.
• Patients were randomized into four groups: placebo, and TTS at 7 mg, 14 mg, and 21 mg daily.
• Both abstinent and non-abstinent smokers were included in the study.

Main Results:

• In abstinent patients, TTS use was associated with decreased systolic blood pressure and heart rate, and increased HDL cholesterol and triglycerides.
• Weight gain was observed in abstinent patients, with greater gain in placebo than 21 mg TTS groups.
• Non-abstinent patients showed increased weight and decreased heart rate; other variables showed no significant changes.

Conclusions:

• Smoking cessation positively impacts cardiovascular risk factors, irrespective of TTS use.
• The transdermal nicotine system appears favorable for cardiovascular health in smoking cessation programs.
• TTS may offer a beneficial method for nicotine replacement during smoking cessation efforts.